Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

12 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability:

		Year Ended December 31,
	Fair Value Hierarchy Level	2022		2021
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively	3	$	27,726	$	—
Non-cash research and development expense		4,951		16,703
Cash receipts from SFJ		750		3,000
Change in the fair value of development derivative liability		(33,427)		8,023
Fair value at end of period	3	$	—	$	27,726